## Clinical Assessment This patient presents with **locally advanced prostate cancer** (cT3b N0 M0) with extraprostatic extension and seminal vesicle invasion. The Gleason score of 8 indicates high-grade disease with intermediate-to-high risk of biochemical recurrence. ## Staging & Risk Stratification **Key Point:** Seminal vesicle involvement (SVI) and extraprostatic extension (EPE) define **locally advanced disease (cT3)**, which is NOT amenable to surgery alone with curative intent. **High-Yield:** According to NCCN and AIIMS guidelines, locally advanced prostate cancer (T3–T4, any N, M0) with high-grade histology (Gleason ≥8) is best managed with **combined modality therapy**: EBRT + long-term ADT (2–3 years). ## Why EBRT + ADT is Optimal | Feature | Rationale | |---------|----------| | **EBRT dose** | 76–80 Gy to prostate + seminal vesicles | | **ADT duration** | 2–3 years (neoadjuvant + concurrent + adjuvant) | | **Outcome** | Improves overall survival vs. EBRT alone in locally advanced disease [cite:RTOG 8531, EORTC 22961] | | **Toxicity** | Acceptable; lower morbidity than radical surgery in this setting | **Clinical Pearl:** Radical prostatectomy is contraindicated in **cT3 disease with SVI** because: 1. Surgical margins are difficult to achieve with SVI involvement. 2. Biochemical recurrence rates are unacceptably high without adjuvant RT. 3. Combined EBRT + ADT provides superior oncologic outcomes in this cohort. ## Why Other Options Are Incorrect **Radical prostatectomy:** While prostatectomy is curative for organ-confined disease, **extraprostatic extension and SVI make it a poor choice** because negative margins cannot be reliably achieved, and adjuvant radiotherapy would still be needed. EBRT + ADT upfront is more effective. **Active surveillance:** Contraindicated in high-grade (Gleason 8) and locally advanced disease. This approach is reserved for low-risk, organ-confined cancers in elderly men with limited life expectancy. **TURP + brachytherapy:** TURP is a palliative procedure for obstructive symptoms, not curative therapy. Brachytherapy is unsuitable for locally advanced disease with SVI because the radiation source cannot adequately cover the seminal vesicles and extraprostatic extension. **High-Yield:** Remember the **treatment algorithm for prostate cancer**: - **Localized (T1–T2, low-intermediate risk):** Surgery, EBRT, or active surveillance. - **Locally advanced (T3–T4):** EBRT + ADT (2–3 years). - **Metastatic:** ADT ± chemotherapy (docetaxel).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.